1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients

Status Completed

Clinical Trial Summary

The purpose of this study is to see if there are any differences in patient reported neurotoxicity between patients who receive Levetiracetam tablets for one week after surgery to remove a brain tumor versus those who receive Levetiracetam tablets for six weeks after surgery. Specifically, we will see if one group has less side effects than the other, and whether or not one group has more seizures than the other.

Clinical Trial Description

Because seizures are one of the leading neurologic complications in brain tumor patients, neurosurgeons prescribe antiepileptic drugs (AEDs) to help prevent them. Although the American Academy of Neurology (AAN) guidelines recommend that AEDs be stopped after the first post-operative week in patients without seizures, there is no standard length of treatment and some patients may stay on AEDs indefinitely. In an attempt to develop clinical guidelines for AED use in post-operative brain tumor patients, we will try to determine if taking levetiracetam for 1 week results in less neurotoxicity than taking it for 6 weeks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02334722
Study type	Interventional
Source	University of Florida
Contact
Status	Completed
Phase	Phase 4
Start date	August 5, 2015
Completion date	October 7, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05023434` - A Study to Measure the Effect of Brain Stimulation on Hand Strength and Function in Patients With Brain Tumors
Terminated	`NCT01902771` - Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors	Phase 1
Completed	`NCT04114786` - 3D Printed Mask for GBM and Brain Mets	N/A
Recruiting	`NCT04367779` - Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
Recruiting	`NCT06058988` - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer	Phase 2
Completed	`NCT02911155` - Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
Completed	`NCT02852655` - A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma	Phase 1
Completed	`NCT01650922` - Molecular Genetic Studies of Childhood Brain Tumors and Blood Samples	N/A
Completed	`NCT00329589` - A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients	Phase 1
Completed	`NCT00505141` - Urban Environmental Exposures and Childhood Cancer	N/A
Completed	`NCT00504660` - 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients	Phase 2
Completed	`NCT00979810` - Image-Guided Stereotactic Biopsy of High Grade Gliomas	N/A
Recruiting	`NCT04899908` - Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases	Phase 2
Active, not recruiting	`NCT02851706` - Natural History of and Specimen Banking for People With Tumors of the Central Nervous System
Completed	`NCT02798406` - Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects	Phase 2
Completed	`NCT01012609` - External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas	Phase 2
Completed	`NCT00782756` - Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma	Phase 2
Terminated	`NCT03149575` - VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM	Phase 3
Completed	`NCT01974804` - Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis
Withdrawn	`NCT01320787` - 18-F-Fluoroacetate as PET Imaging Agent	Phase 1